# Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)

> **NCT01590225** · PHASE3 · WITHDRAWN · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Boceprevir
- **DRUG:** Peginterferon alpha-2b
- **DRUG:** Ribavirin
- **DRUG:** Boceprevir
- **DRUG:** Peginterferon alfa-2b
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01590225
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-01-28
- **Primary completion:** 2021-08-18
- **Final completion:** 2021-08-18
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2021-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01590225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01590225, "Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01590225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*